Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes

NCT03659799 is registered in ClinicalTrials.gov with Institut de Recherches Cliniques de Montreal as lead sponsor.

NCT NCT03659799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes
Lead sponsor
Institut de Recherches Cliniques de Montreal
Phase
Phase 4
Overall status
Completed
Start date
April 12, 2019
Completion date
March 30, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus